Tony Hagen
Articles
Novel Agents, Earlier Diagnosis Driving Survival Gains in CLL
January 03, 2019
Article
The median overall survival for patients with chronic lymphocytic leukemia has more than tripled since the 1970s, primarily due to an ever-expanding armamentarium of novel agents and earlier diagnosis, said Richard Furman, MD, director of the Weill Cornell Medicine CLL Research Center, at the 36th Annual CFS®.
Shared Decision Making Key in Choosing Adjuvant Treatments for Melanoma
November 10, 2018
Article
The fast pace of development in the immunotherapy and targeted therapy space has outstripped the availability of head-to-head comparative data for adjuvant melanoma treatment. Therefore, Hussein Tawbi, MD, PhD, recommended for healthcare professionals to communicate the relative merits and risks of both options to patients and making a shared decision.
Endocrine Therapy May Eliminate Need for Surgery or Chemotherapy for Some Breast Cancer Patients
March 15, 2018
Article
Endocrine therapy can reduce tumor size in patients with ER-positive breast cancer. It can even help some patients avoid chemotherapy or even surgery. Deciding how long to continue this therapy can be tricky though.
Breast Cancer Staging Manual Revised to Highlight Role of Tumor Biology
March 13, 2018
Article
The latest revision of the staging manual for breast cancer from the American Joint Committee on Cancer (AJCC) codifies advanced knowledge of the role of biologic factors in cancer.
Palbociclib Combo Effective in Frontline Treatment of ER+, HER2- Postmenopausal Metastatic Breast Cancer
March 10, 2018
Article
Palbociclib (Ibrance), a CDK 4/6 inhibitor, demonstrated significant efficacy in combination with the aromatase inhibitor letrozole (Femara) in the frontline setting of estrogen receptor (ER)-positive, HER2-negative, postmenopausal metastatic breast cancer in phase III PALOMA-2 study.
CAR T-cell Therapy Introduced With $475,000 Price Tag
August 31, 2017
Article
Tisagenlecleucel (Kymriah), Novartis' newly approved CAR T-cell therapy, will be put on the market with a price of $475,000 for a single infusion, an amount that is within the range anticipated by oncologists and that Novartis characterized as well below a price level that could be justified on cost.
ASCO Calls for Alignment of Drug Costs and Values
July 21, 2017
Article
“If you locked everybody in a room for a week, I think we could come up with something that everybody would be comfortable with,” said Blase Polite, MD, a co-author of the statement, and immediate past chair of ASCO’s government relations committee.
Helping Patients Cope With Care Costs: An Online Boot Camp for Financial Navigators
May 22, 2017
Article
Members of the ACCC have created an online course, Financial Advocacy Boot Camp, to help financial navigators find the funds for their patients.
AHCA Prevails in 217-213 House Vote, but Changes Expected in the Senate
May 05, 2017
Article
The revised American Health Care Act has passed through the House of Representatives.
Patients Often Not as Confident in Their Oral Medication Regimens as They Seem
May 03, 2017
Article
At the 2017 Community Oncology Alliance annual conference, panelists discussed techniques to encourage improved adherence in patients on oral oncology medication.